On October 8, 2026 CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer (mCRC) and metastatic triple-negative breast cancer (mTNBC), reported that updated clinical data from its ongoing Phase 2 CLOVER study (ClinicalTrials.gov Identifier: NCT06699836), evaluating leronlimab in combination with trifluridine and tipiracil ("TAS-102") plus bevacizumab in patients with previously treated mCRC, will be presented at the ESMO (Free ESMO Whitepaper) Congress 2026, taking place October 23–27, 2026, in Madrid, Spain.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the poster presentation are as follows:
Abstract title:
Leronlimab (LRM) in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) in metastatic colorectal cancer (mCRC): The phase 2 CLOVER study
Presenter:
Benjamin Weinberg, M.D., Associate Professor at Georgetown University
Date and Time:
Sunday, October 25, 2026, 12:00-12:45 p.m. CET (local time)
Poster ID:
820P
Location: Poster Area, Hall 5, IFEMA Madrid
"We are excited to present updated findings from the CLOVER study at ESMO (Free ESMO Whitepaper) and share additional clinical and translational insights from our metastatic colorectal cancer program," said Jacob P. Lalezari, M.D., Chief Executive Officer of CytoDyn. "These data will contribute to our understanding of CCR5 biology in colorectal cancer and help inform the continued development of leronlimab in combination with established therapies for patients with difficult-to-treat disease."
A copy of the poster will be made available on CytoDyn’s website under the Publications & Posters section, shortly after the presentation date.
(Press release, CytoDyn, OCT 8, 2026, View Source [SID1234673281])